Famitinib 23 (Fig. 6) is an oral VEGFR-2 and -3 inhibitor used in trial studies against colon and renal cancers.84,85 A promising synergistic effect was observed against NSCLC upon the combination of famitinib with almonertinib (HS-10296, EGFR inhibitor) 24.85 Here, KDR is linked to non-small cell lung carcinoma.